Literature DB >> 11251968

CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking.

C Stratowa1, G Löffler, P Lichter, S Stilgenbauer, P Haberl, N Schweifer, H Döhner, K K Wilgenbus.   

Abstract

Human cancer is characterized by complex molecular perturbations leading to variable clinical behavior, often even in single-disease entities. We performed a feasibility study systematically comparing large-scale gene expression profiles with clinical features in human B-cell chronic lymphocytic leukemia (B-CLL). cDNA microarrays were employed to determine the expression levels of 1,024 selected genes in 54 peripheral blood lymphocyte samples obtained from patients with B-CLL. Statistical analyses were applied to correlate the expression profiles with a number of clinical parameters including patient survival and disease staging. We were able to identify genes whose expression levels significantly correlated with patient survival and/or with clinical staging. Most of these genes code either for cell adhesion molecules (L-selectin, integrin-beta2) or for factors inducing cell adhesion molecules (IL-1beta, IL-8, EGR1), suggesting that prognosis of this disease may be related to a defect in lymphocyte trafficking. This report demonstrates the feasibility of a systematic integration of large-scale gene expression profiles with clinical data as a general approach for dissecting human diseases. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251968     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1078>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Microarray-based expression profiling of normal and malignant immune cells.

Authors:  Rheem D Medh
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

2.  Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.

Authors:  Lynne V Abruzzo; Lynn L Barron; Keith Anderson; Rachel J Newman; William G Wierda; Susan O'brien; Alessandra Ferrajoli; Madan Luthra; Sameer Talwalkar; Rajyalakshmi Luthra; Dan Jones; Michael J Keating; Kevin R Coombes
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

3.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

4.  A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.

Authors:  Sivasubramanian Baskar; Jessica M Suschak; Ivan Samija; Ramaprasad Srinivasan; Richard W Childs; Steven Z Pavletic; Michael R Bishop; Christoph Rader
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

5.  Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression.

Authors:  Y J Lu; D Williamson; J Clark; R Wang; N Tiffin; L Skelton; T Gordon; R Williams; B Allan; A Jackman; C Cooper; K Pritchard-Jones; J Shipley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

6.  High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

Authors:  Jana Kotaskova; Boris Tichy; Martin Trbusek; Hana Skuhrova Francova; Jitka Kabathova; Jitka Malcikova; Michael Doubek; Yvona Brychtova; Jiri Mayer; Sarka Pospisilova
Journal:  J Mol Diagn       Date:  2010-03-12       Impact factor: 5.568

7.  Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males.

Authors:  Jean-Brice Marteau; Odile Rigaud; Thibaut Brugat; Nathalie Gault; Laurent Vallat; Mogens Kruhoffer; Torben F Orntoft; Florence Nguyen-Khac; Sylvie Chevillard; Hélène Merle-Beral; Jozo Delic
Journal:  BMC Med Genomics       Date:  2010-11-10       Impact factor: 3.063

8.  A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Authors:  Daphne R Friedman; J Brice Weinberg; William T Barry; Barbara K Goodman; Alicia D Volkheimer; Karen M Bond; Youwei Chen; Ning Jiang; Joseph O Moore; Jon P Gockerman; Louis F Diehl; Carlos M Decastro; Anil Potti; Joseph R Nevins
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

9.  Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression.

Authors:  Han-Yu Chuang; Laura Rassenti; Michelle Salcedo; Kate Licon; Alexander Kohlmann; Torsten Haferlach; Robin Foà; Trey Ideker; Thomas J Kipps
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

10.  Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

Authors:  Robert S Boyd; Rebekah Jukes-Jones; Renata Walewska; David Brown; Martin J S Dyer; Kelvin Cain
Journal:  Mol Cell Proteomics       Date:  2009-04-02       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.